The Competition Commission of India (CCI) has put the Holcim-Lafarge deal under public scrutiny after prima facie finding it could hurt competition in Indian cement market. This is the second deal, after the proposed $4 billion Sun Pharma-Ranbaxy transaction, wherein the regulator is seeking comments from the public to assess fair competition concerns before taking the final call.